EGFR and lung carcinoma: Interestingly, by integrating mRNA expression data of EGFR-mutated lung cancer patients from TCGA and the drug sensitivity data in the GDSC database, we found that for small molecule EGFR-TKI drugs (e.g., gefitinib, erlotinib), high ACACA expression in the EGFR-mutated group was associated with increased IC50 value.